[144] Atlassian Corporation SEC Filing
Rhea-AI Filing Summary
Atlassian Corporation (TEAM) Form 144 notice shows a proposed sale of 1,682 restricted common shares, acquired from the issuer on 08/18/2025, with an aggregate market value of $280,268.13 and an approximate sale date of 08/19/2025 on NASDAQ. The filing reports 262,334,536 shares outstanding for the issuer. The securities will be transacted through Morgan Stanley Smith Barney LLC as broker. The filing also discloses a prior sale by the same person: 7,728 shares sold on 08/14/2025 for gross proceeds of $1,262,954.58, attributed to ANUTTHARA BHARADWAJ. The signer represents no undisclosed material adverse information and notes the Rule 144 sale certification requirements.
Positive
- Filing compliance: The Form 144 includes required disclosures and the seller's certification regarding material nonpublic information
- Execution through major broker: The sale is to be handled by Morgan Stanley Smith Barney LLC, a recognized brokerage firm
Negative
- Insider selling activity: 7,728 shares were sold on 08/14/2025 for $1,262,954.58 and an additional 1,682 shares (value $280,268.13) are proposed for sale, which may concern some investors
- No stated 10b5-1 adoption date: The filing references Rule 10b5-1 language but does not disclose whether a written trading plan governs the proposed sale
Insights
TL;DR: Insider filing indicates routine restricted-share distribution and recent insider sales totaling ~9,410 shares.
The Form 144 documents a near-term sale of 1,682 restricted shares received from the issuer on 08/18/2025 and cleared for resale the following day, plus a recent sale of 7,728 shares generating $1.26 million on 08/14/2025. These entries reflect disposition activity by a related person rather than an operational development for the company. The broker listed is Morgan Stanley Smith Barney LLC, indicating a standard brokerage execution. Impact on the company's outstanding share base is negligible given the reported 262.3 million shares outstanding, so market-moving implications are likely limited unless additional, larger insider sales follow.
TL;DR: Filing appears procedurally compliant with Rule 144 disclosures and contains the required signer representation.
The notice includes the required representation that no material nonpublic information is known to the seller and references Rule 10b5-1 plan language if applicable, but does not state a plan adoption date. The acquisition is documented as restricted stock from the issuer with same-day payment, and a reputable broker is named for execution. From a governance perspective, the form meets standard disclosure elements; the absence of an explicit 10b5-1 adoption date limits clarity on whether the sale follows a pre-authorized plan.